Hutchison China Meditech Limited Director's Share Dealing (3158M)
12 October 2016 - 5:00PM
UK Regulatory
TIDMHCM
RNS Number : 3158M
Hutchison China Meditech Limited
12 October 2016
Director's Share Dealing
London: Wednesday, October 12, 2016: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification
that Mr Michael Howell, Independent Non-executive Director, has
sold 15,000 ordinary shares of US$1.00 each in Chi-Med (the
"Ordinary Shares") at a price of GBP17.90 per share on October 7,
2016.
Following the above transaction, the holding of Mr Howell is
138,600 Ordinary Shares, representing approximately 0.23% of the
current issued share capital of Chi-Med.
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Mr Michael Howell
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
a) Position/status Independent Non-executive Director of Chi-Med
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI N/A
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Ordinary Shares of US$1.00 each
instrument DI ISIN: KYG4672N1016
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Sale of 15,000 Ordinary Shares on October 7, 2016 at
a price of GBP17.90
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP17.90 15,000
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2016-10-07
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction London Stock Exchange (XLON)
---- ------------------------------------------------------- -------------------------------------------------------
NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1-646-378-2933 (Mobile) mbeck@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFSEIVLFLIR
(END) Dow Jones Newswires
October 12, 2016 02:00 ET (06:00 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024